News | January 06, 2014

Studies Assessing Stentys in Indications Outside of Heart Attacks Presented at TCT 2013

stentys self-apposing stent clinical trial study TCT 2013 cath lab
January 6, 2014 — Stentys, developer of the world's first self-apposing stent to treat acute myocardial infarction (AMI), announced new data in indications outside of myocardial infarction. Results from the OPEN II study and a series from the Amsterdam Medical Center were presented during the TCT conference (TCT 2013) in San Francisco.
 
OPEN II is a prospective, single-arm trial that enrolled 217 patients treated for chest pain due to a narrowing at a coronary artery bifurcation with the Stentys paclitaxel-eluting stent in 21 hospitals in six European countries. The primary endpoint of MACE (composite of cardiac death, myocardial infarction, emergent bypass surgery and target lesion revascularization) at six months was 10.1 percent for the whole study group, with a rate of 6.9 percent in patients with simple lesions. Christoph Naber, M.D., Ph.D., Contilia Heart and Vascular Center, Essen, Germany, and principal investigator of the study, presented the results.
 
“This large study in a highly complex group of patients with challenging lesions confirms that the Stentys stent can be used in routine practice and leads to very good results compared to those published historically,” said Naber.
 
Huangling Lu, M.D., from Amsterdam Medical Center, Netherlands, also presented a series of 87 patients treated with Stentys at her institution. This series enrolled primarily patients with atypical anatomy: 53 percent had aneurysmatic or ectactic vessels, 31 percent had tapered vessels, 23 percent had large vessels (above 4.5 mm) and 10 percent had bypass grafts. At 12 months, the MACE rate was 4.7 percent.
 
“The Self-Apposing stent is the only available product that can conform to complex, non-cylindrical vessel anatomy, as detailed on its recently extended CE mark label,” said Gonzague Issenmann, CEO and co-founder, Stentys.
 
The Stentys Self-Apposing stent is engineered to solve the dilemma of artery diameter discrepancy. Its flexible, self-expanding design takes the shape of the patient’s unique vessel anatomy and apposes to the irregular contours of a blood vessel.
 
For more information: www.stentys.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init